TOPLINE: In a recent final analysis of a phase 3 trial, the b ivalent respiratory syncytial virus prefusion F (RSVpreF) vaccine maintained high efficacy and a favorable safety profile against RSV-associated lower respiratory tract illness (RSV-LRTI) over two seasons in people aged ≥ 60 years. METHODOLOGY: Researchers present the final results of a phase 3, […]
The post Sustained Protection of Bivalent RSV Vaccine for Seniors first appeared on News Health.
Author : News Health
Publish date : 2025-03-24 12:02:00
Copyright for syndicated content belongs to the linked Source.